ASX Announcements

BioDiem is dedicated to maintaining open lines of communication.
ASX Announcements
2012
9 Feb BioDiem Licenses LAIV Technology
24 Jan Appendix 4C - Quarterly Update
2011
15 Dec New issue announcement
14 Dec BioDiem acquires Savine Therapeutics Pty Ltd
15 Nov Investor Presentation
28 Oct Appendix 4C - Quarterly Update
 20 Oct Results of Meeting
 20 Oct AGM Presentation
 20 Oct AGM Chairman's Address
11 Oct BioPartnering Europe Presentation
10 Oct Investor Presentation
19 Sept AGM - Notice of Meeting
19 Sept Annual Report
26 Aug Full Year Results Commentary
26 Aug Appendix 4E
1 Aug BioDiem Licenses LAIV Technology to Serum Institute of India
1 Aug BioDiem Replaces Nobilon as Licensor of LAIV Technology to the World Health Organization
1 Aug BioDiem Regains Rights to LAIV Technology
28 Jul Amended Securities Guidelines
28 Jul Appendix 4C - Quarterly Update
29 Apr Appendix 4C - Quarterly Update
28 Feb Half Year Financial Results
28 Feb Half Year Financial Report
28 Jan Appendix 4C - Quarterly Update
4 Jan Securities Guidelines
2010
16 Dec US$0.25m Royalties Received on Nasovac Sales
1 Dec US & China Patents Granted for BDM-I
29 Oct Appendix 4C - Quarterly Report
11 Oct Merck/Schering-Plough Update
23 Sept Results of Annual General Meeting
23 Sept AGM Presentations
23 Sept Chairman's Address to Shareholders
21 Sept Placement of $1m of Rights Issue Shortfall
21 Sept Rights Issue Update - Appendix 3B
15 Sept Appointment of Projects Manager
9 Sept
FDA Grants Orphan Drug Status to BDM-E
8 Sept LAIV Featured at International Conference
7 Sept
Notice of Meeting and Proxy Form
23 Aug Annual Report
19 Aug
Financial Results
30 Jul
Appendix 4C - Quarterly Report
12 Jul LAIV Launched in India
25 Jun Rights Issue Update
24 Jun Notice of Undersubscriptions
12 May Supplementary Prospectus
10 May
EGM Results
7 May Board Changes
30 Apr Appendix 4C - Quarterly Report
23 Apr Roadshow Presentation
12 Apr
Prospectus
12 Apr
Notice of Meeting - Proxy and Independent Reports
31 Mar
Pandemic Influenza Vaccines Update
30 Mar
Letter to Shareholders
26 Mar
Appendix 3B Pro Rata
25 Mar Rights Issue
25 Mar
Appendix 3B
25 Mar Appendix 3B
26 Feb Shareholder Update
26 Feb Half Year Financial Results
26 Feb Half Year Financial Report
29 Jan Appendix 4C - Quarterly Report
 
2009
27 Oct WHO Chinese Sublicence
27 Oct CRADA Extention
22 Oct Appendix 4C - Quarterly Report
14 Oct LAIV Proof of Concept Trial
24 Sept Annual General Meeting Results
24 Sept Annual General Meeting Presentations
2 Sept WHO Sublicenses LAIV Technology for Global Pandemic Influenza Action Plan
1 Sept Agreement with PATH for Prototype Pandemic Influenza Vaccine
31 Aug
Completion of Phase I Clinical Trial for LAIV Technology
24 Aug Annual Report
24 Aug Notice of Meeting
19 Aug Preliminary Financial Results
31 Jul
Appendix 4C - Quarterly Report
14 Jul
CEO Appointment
25 Jun Appendix 3B
8 May
Appendix 3Y
28 Apr
Appendix 4C - Quarterly Report
22 Apr
Appendix 3Y
26 Feb Half Year Financial Results
24 Feb Commencement of Phase I Clinical Trial for LAIV
5 Feb
Board Changes
30 Jan Appendix 4C - Quarterly Report